Dear Autism Community,

We are continuing to make good progress with our clinical trials of Microbiota Transplant Therapy (MTT) for autism and related conditions, including:

• Substantial improvements in GI and autism symptoms
• Great safety, with zero serious adverse effects
• 60 children with autism enrolled in our newest clinical trial.

Hear from parents how MTT has helped their children and adults with autism:

 https://youtu.be/QqJpAacR66c

Investing:  Our clinical trials are funded by our new company, Gut-Brain-Axis Therapeutics Inc (GBAT), which has raised over $6 million from over 60 autism family investors. We are inviting additional families to consider purchasing stock in GBAT to help us achieve FDA approval of MTT for autism.

Consider attending a webinar for Potential Investors to learn more:

Tuesday October 15 8:30 pm Eastern (5:30 pm Pacific)

Meeting Registration - Zoom

Monday October 21 8;30 pm Easter (5:30 pm Pacific)

Meeting Registration - Zoom

Thursday October 24 1:00 pm Eastern (10 am Pacific)

Meeting Registration - Zoom

If the dates/times above are not possible for you, we can schedule another date/time– email james@gutbrainaxistherapeutics.com

Accredited Investors: Due to federal regulations, purchasing stock in private companies like GBAT is only available to people who qualify as “accredited investors”, which generally means they either have a high income ($200,000/yr, or $300,000/yr with spouse) or $1 million in assets (not including their personal home, but including retirement funds and other assets).

Thanks for your interest in Microbiota Transplant Therapy for Autism!

Sincerely,

James B. Adams, PhD

proud father of a daughter with autism

President, Gut-Brain-Axis Therapeutics Inc

james@gutbrainaxistherapeutics.com

https://gutbrainaxistherapeutics.com/

https://www.linkedin.com/company/gut-brain-axis-therapeutics/